MYCOLab Ai Logo - gold and army green

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Summary

This study tested a new antifungal drug called SF001 against a serious infection called fusariosis in mice. SF001 performed as well as the current standard treatment (amphotericin B) but with better safety profiles. The drug successfully reduced fungal infections in organs and improved survival rates in infected mice without showing signs of toxicity at higher doses.

Background

Fusariosis has high mortality rates with limited treatment options, particularly in immunocompromised patients with hematologic malignancies. Current treatments with amphotericin B (AMB) and liposomal amphotericin B (LAMB) are associated with significant toxicities. SF001 is a novel, next-generation polyene drug designed to maintain potency while reducing systemic toxicity.

Objective

To compare the in vitro activity and in vivo efficacy of SF001 with liposomal amphotericin B in treating immunosuppressed mice infected with hematogenously disseminated fusariosis caused by Fusarium solani and Fusarium oxysporum.

Results

SF001 demonstrated more favorable in vitro activity with MIC values of 0.5-8 µg/mL compared to LAMB at 1->16 µg/mL. In vivo, SF001 at 7.5 and 30 mg/kg showed 40% and 25% survival rates by day 21, comparable to LAMB at 30%. Both treatments achieved 2-3 log₁₀ reduction in kidney and brain fungal burden and showed reduced or absent abscesses on histopathology.

Conclusion

SF001 demonstrated comparable efficacy to the current standard of care LAMB in treating invasive fusariosis in neutropenic mice. The drug was well tolerated at high doses with no visible toxicity, supporting continued development of SF001 for treating invasive fusariosis.
  • Published in:Antimicrobial Agents and Chemotherapy,
  • Study Type:Preclinical Animal Study,
  • Source: 10.1128/aac.01802-24
Scroll to Top